References
- Ahteensuu, M. 2017. “Synthetic Biology, Genome Editing, and the Risk of Bioterrorism.” Science and Engineering Ethics 23 (6): 1541–1561. doi:https://doi.org/10.1007/s11948-016-9868-9.
- Alphey, L. 2016. “Can CRISPR-Cas9 Gene Drives Curb Malaria?” Nature Biotechnology 34 (2): 149–150. doi:https://doi.org/10.1038/nbt.3473.
- Asquer, A., and I. Krachkovskaya. 2020. “Uncertainty, Institutions and Regulatory Responses to Emerging Technologies: CRISPR Gene Editing in the US and the EU (2012–2019). Regulation & Governance. doi:https://doi.org/10.1111/rego.12335.
- Ayres, R. U., and A. V. Kneese. 1969. “Production, Consumption, and Externalities.” The American Economic Review 59 (3): 282–297. https://www.jstor.org/stable/1808958
- Baltimore, David, Paul Berg, Michael Botchan, Dana Carroll, R. Alta Charo, George Church, Jacob E. Corn, et al. 2015. “ Biotechnology. A Prudent Path Forward for Genomic Engineering and Germline Gene Modification.” Science 348 (6230): 36–38. doi:https://doi.org/10.1126/science.aab1028.
- Barzelay, M. 2007. “Learning from Second‐Hand Experience: Methodology for Extrapolation‐Oriented Case Research.” Governance 20 (3): 521–543. doi:https://doi.org/10.1111/j.1468-0491.2007.00369.x.
- Burall, S. 2018. “Rethink Public Engagement for Gene Editing.” Nature 555 (7697): 438–439. doi:https://doi.org/10.1038/d41586-018-03269-3.
- Candela, G., M. Castellani, and R. Dieci. 2008. “Economics of Externalities and Public Policy.” International Review of Economics 55 (3): 285–311. doi:https://doi.org/10.1007/s12232-008-0045-6.
- Capano, G., and M. Howlett. 2021. “Causal Logics and Mechanisms in Policy Design: How and Why Adopting a Mechanistic Perspective Can Improve Policy Design.” Public Policy and Administration 36 (2): 141–162. doi:https://doi.org/10.1177/0952076719827068.
- Capano, G., Howlett, M., Ramesh, M., & Virani, A. (Eds.) 2019. Making Policies Work: First-and Second-Order Mechanisms in Policy Design. Cheltenham: Edward Elgar Publishing.
- Charo, R. A., and H. T. Greely. 2015. “CRISPR Critters and CRISPR Cracks.” The American Journal of Bioethics 15 (12): 11–17. doi:https://doi.org/10.1080/15265161.2015.1104138.
- Chen, K., Y. Wang, R. Zhang, H. Zhang, and C. Gao. 2019. “CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture.” Annual Review of Plant Biology 70: 667–697. doi:https://doi.org/10.1146/annurev-arplant-050718-100049.
- Chertow, D. S. 2018. “Next-Generation Diagnostics with CRISPR.” Science 360 (6387): 381–382. doi:https://doi.org/10.1126/science.aat4982.
- Chow, R. 2008. “Case Transfer vs. Case Study: An Evaluation of Case Study as a Method for Design Research.” Proceeding of“Focused” – Current Design Research Projects and Methods, 41–53.
- Cohen, J. 2017. “The Birth of CRISPR Inc.” Science 355 (6326): 680–684. doi:https://doi.org/10.1126/science.355.6326.680.
- Cornes, R., and T. Sandler. 1996. The Theory of Externalities. Public Goods, and Club Goods. Cambridge, MA: Cambridge University Press.
- Costa‐Font, J., E. Mossialos, and C. Rudisill. 2009. “Optimism and the Perceptions of New Risks.” Journal of Risk Research 12 (1): 27–41. doi:https://doi.org/10.1080/13669870802445800.
- Courtier-Orgogozo, V., B. Morizot, and C. Boëte. 2017. “Agricultural Pest Control with CRISPR-Based Gene Drive: Time for Public Debate: Should we use Gene Drive for Pest Control?” EMBO Reports 18 (6): 878–880. doi:https://doi.org/10.15252/embr.201744205.
- Cox, D. B. T., R. J. Platt, and F. Zhang. 2015. “Therapeutic Genome Editing: Prospects and Challenges.” Nature Medicine 21 (2): 121–131. doi:https://doi.org/10.1038/nm.3793.
- Entine, J., M. S. S. Felipe, J. H. Groenewald, D. L. Kershen, M. Lema, A. McHughen, A. L. Nepomuceno, et al. 2021. “Regulatory Approaches for Genome Edited Agricultural Plants in Select Countries and Jurisdictions around the World.” Transgenic Research. doi:https://doi.org/10.1007/s11248-021-00257-8.
- Evitt, N. H., S. Mascharak, and R. B. Altman. 2015. “Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.” The American Journal of Bioethics 15 (12): 25–29. doi:https://doi.org/10.1080/15265161.2015.1104160.
- Fischhoff, B., and D. A. Scheufele. 2013. “The Science of Science Communication.” Proceedings of the National Academy of Sciences 110 (Supplement_3): 14031–14032. doi:https://doi.org/10.1073/pnas.1312080110.
- Foss, D. V., M. L. Hochstrasser, and R. C. Wilson. 2019. “Clinical Applications of CRISPR-based genome editing and diagnostics.” Transfusion 59 (4): 1389–1399. doi:https://doi.org/10.1111/trf.15126.
- Fraser, C. M., and M. R. Dando. 2001. “Genomics and Future Biological Weapons: The Need for Preventive Action by the Biomedical Community.” Nature Genetics 29 (3): 253–256. doi:https://doi.org/10.1038/ng763.
- Friedmann, T. 2019. “Genetic Therapies, Human Genetic Enhancement, and … Eugenics.” Gene Therapy 26 (9): 351–354. doi:https://doi.org/10.1038/s41434-019-0088-1.
- Gori, J. L., P. D. Hsu, M. L. Maeder, S. Shen, G. G. Welstead, and D. Bumcrot. 2015. “Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy.” Human Gene Therapy 26 (7): 443–451. doi:https://doi.org/10.1089/hum.2015.074.
- Guttinger, S. 2018. “Trust in Science: CRISPR-Cas9 and the Ban on Human Germline Editing.” Science and Engineering Ethics 24 (4): 1077–1096. doi:https://doi.org/10.1007/s11948-017-9931-1.
- Hathaway, D., and P. Norton. 2018. Understanding Problems of Practice: A Case Study in Design Research. New York: Springer International Publishing.
- Herring, R., and R. Paarlberg. 2016. “The Political Economy of Biotechnology.” Annual Review of Resource Economics 8 (1): 397–416. doi:https://doi.org/10.1146/annurev-resource-100815-095506.
- Hood, C. 1986. The Tools of Government. Chatham, NJ: Chatham House.
- Kosal, M. E. 2020. “Emerging Life Sciences and Possible Threats to International Security.” Orbis 64 (4): 599–614. doi:https://doi.org/10.1016/j.orbis.2020.08.008.
- Krippendorff, K. 2005. The Semantic Turn: A New Foundation for Design. Boca Raton, FL: CRC Press.
- Kupferschmidt, K. 2018. “EU Verdict on CRISPR Crops Dismays Scientists.” Science 361 (6401): 435–436.
- Kwakkel, J. H., M. Haasnoot, and W. E. Walker. 2016. “Coping with the Wickedness of Public Policy Problems: Approaches for Decision-Making under Deep Uncertainty.” Journal of Water Resources Planning and Management 142 (3): 01816001. doi:https://doi.org/10.1061/(ASCE)WR.1943-5452.0000626.
- Lee, M., and H. Kim. 2019. “Therapeutic Application of the CRISPR System: Current Issues and New Prospects.” Human Genetics 138 (6): 563–590. doi:https://doi.org/10.1007/s00439-019-02028-2.
- Mandel, G. N. 2009. “Regulating Emerging Technologies.” Law, Innovation and Technology 1 (1): 75–92. doi:https://doi.org/10.1080/17579961.2009.11428365.
- Maor, M. 2012. “Policy Overreaction.” Journal of Public Policy 32 (3): 231–259. doi:https://doi.org/10.1017/S0143814X1200013X.
- Maor, M. 2014. “Policy Bubbles: Policy Overreaction and Positive Feedback.” Governance 27 (3): 469–487. doi:https://doi.org/10.1111/gove.12048.
- McFarlane, G. R., C. B. A. Whitelaw, and S. G. Lillico. 2018. “CRISPR-Based Gene Drives for Pest Control.” Trends in Biotechnology 36 (2): 130–133. doi:https://doi.org/10.1016/j.tibtech.2017.10.001.
- Mehravar, M.,. A. Shirazi, M. Nazari, and M. Banan. 2019. “Mosaicism in CRISPR/Cas9-Mediated Genome Editing.” Developmental Biology 445 (2): 156–162. doi:https://doi.org/10.1016/j.ydbio.2018.10.008.
- Pollack, R. 2015. “Eugenics Lurk in the Shadow of CRISPR.” Science 348 (6237): 871. doi:https://doi.org/10.1126/science.348.6237.871-a.
- Roca, J. B., P. Vaishnav, M. G. Morgan, J. Mendonça, and E. Fuchs. 2017. “When Risks Cannot Be Seen: Regulating Uncertainty in Emerging Technologies.” Research Policy 46 (7): 1215–1233. doi:https://doi.org/10.1016/j.respol.2017.05.010.
- Sabatier, P. A. 1988. “An Advocacy Coalition Framework of Policy Change and the Role of Policy-Oriented Learning Therein.” Policy Sciences 21 (2–3): 129–168. doi:https://doi.org/10.1007/BF00136406.
- Sarewitz, D. 2015. “CRISPR: Science Can’t Solve It.” Nature News 522 (7557): 413–414. doi:https://doi.org/10.1038/522413a.
- Teegavarapu, S., J. D. Summers, and G. M. Mocko. 2008. “Case Study Method for Design Research: A Justification.” In International Design Engineering Technical Conferences and Computers and Information in Engineering Conference Proceedings, 43284, 495–503.
- Tylecote, A. 2019. “Biotechnology as a New Techno-Economic Paradigm That Will Help Drive the World Economy and Mitigate Climate Change.” Research Policy 48 (4): 858–868. doi:https://doi.org/10.1016/j.respol.2018.10.001.
- Webber, B. L., S. Raghu, and O. R. Edwards. 2015. “Opinion: Is CRISPR-Based Gene Drive a Biocontrol Silver Bullet or Global Conservation Threat?” Proceedings of the National Academy of Sciences of the United States of America 112 (34): 10565–10567. doi:https://doi.org/10.1073/pnas.1514258112.
- Weible, C. M. 2005. “Beliefs and Perceived Influence in a Natural Resource Conflict: An Advocacy Coalition Approach to Policy Networks.” Political Research Quarterly 58 (3): 461–475. doi:https://doi.org/10.1177/106591290505800308.
- Weible, C. M., and P. A. Sabatier. 2017. “A Guide to the Advocacy Coalition Framework.” In Handbook of Public Policy Analysis: Theory, Politics, and Methods, edited by F. Fischer & G. J. Miller, 149–162. London: Routledge.
- Weingart, P., and L. Guenther. 2016. “Science Communication and the Issue of Trust.” Journal of Science Communication 15 (5): C01–C11. doi:https://doi.org/10.22323/2.15050301.
- Williams, G. A., S. Liede, N. Fahy, K. Aittomaki, M. Perola, T. Helander, M. McKee, and A. Sagan. 2021. Regulating the Unknown: A Guide to Regulating Genomics for Health Policy-Makers. Copenhagen: European Observatory on Health System and Policies, Policy Brief, 38.
- Zettler, P. J., C. J. Guerrini, and J. S. Sherkow. 2019. “Regulating Genetic Biohacking.” Science 365 (6448): 34–36. doi:https://doi.org/10.1126/science.aax3248.